Overcoming Antibody Discovery Challenges Against GPCR Targets
Generate high-quality therapeutic leads for GPCR targets in just 12 weeks with next-generation antibody discovery workflows The therapeutic promise of GPCR-targeted monoclonal antibodies G protein-coupled receptors (GPCRs) represent the largest family of cell surface receptors, serving as critical signaling nodes across all major physiological systems. These seven-transmembrane proteins control essential functions in metabolism, immunity, and […]
Poster | A Fully Integrated GPCR Antibody Discovery Workflow
Overcoming challenges in GPCRs with a fully integrated high-throughput antibody discovery workflow Download the poster Contact Us Poster Overview: Transform your approach to GPCR antibody discovery with this detailed poster that demonstrates how Alloy Therapeutics’ PerformAbTM yeast display platform and innovative technologies can overcome significant challenges in targeting these complex transmembrane proteins. Download the poster […]
Alloy Therapeutics and Kansai Startup Academia Coalition (KSAC) Announce Strategic Collaboration to Accelerate Global Growth of Japanese Life Science Startups
Advancing Japan’s academic biotech through global partnerships and support for real-world therapeutic development.
Alloy Therapeutics Signs Memorandum of Understanding (MOU) with the Republic of Serbia to Support Global Bioeconomy Initiative
The collaboration extends Alloy’s sovereign innovation efforts to help advance Serbia’s national biotech ambitions through the BIO4 Campus.
Identify functional chimeric antigen receptors three months faster with Alloy’s end-to-end CAR discovery
Webinar overview: Looking for a way to accelerate your CAR-T therapeutic development projects? This presentation highlights how Alloy’s comprehensive platform and expertise can enable you to: Streamline end-to-end CAR discovery: Learn how Alloy’s full stack technologies enable discovery and screening of functional CARs with unprecedented speed and cost efficiency, overcoming limitations of conventional two-step processes. […]
Leveraging Human Lambda Light Chains in Antibody Discovery
Harnessing the potential of human lambda light chains in antibody discovery Download White Paper Contact Us Expanding antibody discovery potential with human lambda light chains Despite the kappa/lambda ratio in human circulation being between 1.5 and 2, therapeutic antibodies remain heavily biased toward kappa light chain usage. Our white paper explores how Alloy’s ATX-GL platform […]
米アロイ・セラピューティクス、 湘南ヘルスイノベーションパークに新拠点を設立
– 米バイオテクノロジー企業、アロイ・セラピューティクスが日本初の子会社を設立
– 主要モダリティである細胞治療の研究拠点を初めて日本に開設し、独自のiCAR-T技術を本格的に展開
Alloy Therapeutics enters Japanese market by establishing operations at Shonan Health Innovation Park
US-based biotech ecosystems company establishes subsidiary in key Japanese market with launch of its first cell therapy base in Japan, a key modality for Alloy to fully advance its proprietary iCAR-T technology.
Discover TCR mimic antibodies that Target Previously “Undruggable” Intracellular Proteins with Keyway™ TCR
Webinar Overview: Unlock access to intracellular protein targets and maximize TCRm/TCR-based therapeutic antibody discovery with this presentation by Dr. Dongxing Zha that reveals how Alloy’s proprietary Keyway™ TCRm Discovery Platform and expertise can: Overcome challenges to intracellular protein-targeted drug discovery: Learn how the Keyway™ TCRm Discovery Platform identifies TCR mimic (TCRm) antibodies that target intracellular […]
Accelerating Bispecific Discovery with the Alloy Common Light Chain Platform
Webinar Overview Discover the full potential of bispecific antibody therapeutics and how to accelerate their discovery during this presentation by Dr. Lucy Liu that reveals how Alloy’s technologies, services, and expertise is able to: Accelerate bispecific antibody discovery: Learn how the Alloy Common Light Chain (CLC) human, transgenic platform streamlines bispecific antibody discovery and development, […]